이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Resonance Health 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Andrew Harrison

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	7.7yrs

최근 관리 업데이트

Recent updates

We're Interested To See How Resonance Health (ASX:RHT) Uses Its Cash Hoard To Grow

Mar 12

Resonance Health (ASX:RHT) Is In A Good Position To Deliver On Growth Plans

Aug 19

Are Robust Financials Driving The Recent Rally In Resonance Health Limited's (ASX:RHT) Stock?

Mar 01

If You Had Bought Resonance Health (ASX:RHT) Stock Three Years Ago, You Could Pocket A 855% Gain Today

Jan 15

How Does Resonance Health's (ASX:RHT) CEO Salary Compare to Peers?

Nov 22

CEO

Andrew Harrison (53 yo)

less than a year

테뉴어

Mr. Andrew Duncan Harrison, BCom (Hons), MAICD was the Managing Director and Chief Executive Officer of Capitol Health Limited since November 11, 2016 until June 30, 2019. He serves as Chief Executive Offi...

리더십 팀

이름	위치	테뉴어	보상	소유권
Mitchell Wells	Company Secretary & Non Executive Director	2.3yrs	AU$322.88k	0.36% A$ 95.0k
Andrew Harrison	Chief Executive Officer	less than a year	데이터 없음	데이터 없음
Benjamin Carruthers	Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Liesl Ellies	General Counsel	no data	데이터 없음	데이터 없음
Chad Tondut	Communications Manager and GM of Products & Portfolio	no data	데이터 없음	데이터 없음
Ajay Nair	General Manager of Global Sales & Marketing	no data	데이터 없음	데이터 없음
Timothy St. Pierre	Chief Research Scientist	no data	AU$206.94k	데이터 없음
Wenjie Pang	Chief Scientific Officer – Imaging & AI	no data	데이터 없음	데이터 없음
Sherif Boulos	Chief Scientific Officer of Molecular	no data	데이터 없음	데이터 없음

1.0yrs

평균 재임 기간

경험이 풍부한 관리: RHT 의 관리팀은 경험 (평균 재직 기간 0.9 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Mitchell Wells	Company Secretary & Non Executive Director	6.4yrs	AU$322.88k	0.36% A$ 95.0k
Simon Panton	Non-Executive Director	14.8yrs	AU$40.00k	16.75% A$ 4.4m
Travis Baroni	Independent Non-Executive Director	7.7yrs	AU$40.00k	0.25% A$ 66.7k
Martin Peter Blake	Independent Non-Executive Chairman	16.8yrs	AU$60.00k	1.45% A$ 381.4k
Aaron Brinkworth	Non-Executive and Independent Director	1.3yrs	AU$11.64k	0.067% A$ 17.7k

7.7yrs

평균 재임 기간

경험이 풍부한 이사회: RHT 의 이사회는 경험(평균 재직 기간 7.6 년)으로 간주됩니다.

Resonance Health 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Resonance Health Limited, Annual General Meeting, Nov 16, 2023

Resonance Health Ltd Appoints Benjamin Carruthers as Chief Financial Officer, Effective October 2023

Resonance Health Limited Announces Resignation of Liesl Ellies as Joint Company Secretary

Insufficient new directors

Resonance Health Limited, Annual General Meeting, Nov 24, 2022

Resonance Health Limited Appoints Liesl Ellies as Joint Company Secretary

Recent updates

We're Interested To See How Resonance Health (ASX:RHT) Uses Its Cash Hoard To Grow

New minor risk - Share price stability

New minor risk - Share price stability

Resonance Health Limited, Annual General Meeting, Nov 16, 2023

Resonance Health Ltd Appoints Benjamin Carruthers as Chief Financial Officer, Effective October 2023

Resonance Health Limited Announces Resignation of Liesl Ellies as Joint Company Secretary

Full year 2023 earnings released: AU$0.002 loss per share (vs AU$0.002 loss in FY 2022)

New minor risk - Financial data availability

Resonance Health (ASX:RHT) Is In A Good Position To Deliver On Growth Plans

First half 2023 earnings released: EPS: AU$0 (vs AU$0 in 1H 2022)

Resonance Health Ltd Announces That It Has Lodged Provisional Patent Application in Relation to an Invention for the Detection and Assessment of Fibrosis in the Liver and Other Organ

Insufficient new directors

Resonance Health Limited, Annual General Meeting, Nov 24, 2022

Full year 2022 earnings released: AU$0.002 loss per share (vs AU$0.001 profit in FY 2021)

Full year 2022 earnings released: AU$0.002 loss per share (vs AU$0.001 profit in FY 2021)

FerriScan Now Available on 3 Tesla (3T) MRI Machines

Resonance Health Limited Appoints Liesl Ellies as Joint Company Secretary

Insufficient new directors

Resonance Health Limited Receives United States CPT Code Confirmation for Liversmart

Resonance Health Limited Announces US FDA Clearance for LiverSmart

Resonance Health Ltd Provides Update on its Antisense Oligonucleotide Project for Treating Viral Hepatitis

Resonance Health Limited Announces Filing of Two Patent Applications

Full year 2021 earnings released: EPS AU$0.001 (vs AU$0.002 loss in FY 2020)

Resonance Health Ltd announces R&D Molecular Medicine ASON Project Results of Dosing Study

Full year 2021 earnings released: EPS AU$0.001 (vs AU$0.002 loss in FY 2020)

Chief Executive Officer Alison Laws has left the company

Resonance Health Limited Announces Filing of Patent Application

Resonance Health Limited Provides Update on Its Antisense Oligonucleotide R&D Project for Treating Liver Related Diseases

Are Robust Financials Driving The Recent Rally In Resonance Health Limited's (ASX:RHT) Stock?

Resonance Health Ltd HepaFat-AI Receives CE Marking

Resonance Health Ltd Receives Australian Therapeutic Goods Administration Approval for HepaFat-AI

If You Had Bought Resonance Health (ASX:RHT) Stock Three Years Ago, You Could Pocket A 855% Gain Today

Resonance's HepaFat-AI Incorporated into Blackford Analysis

New 90-day high: AU$0.28

How Does Resonance Health's (ASX:RHT) CEO Salary Compare to Peers?

Resonance Health Ltd Develops New Artificial Intelligence Tool for the Automated Review of Chest Computed Tomography Scans of Patients with Suspected Pulmonary Embolism

Full year earnings released - AU$0.0017 loss per share

Full year earnings released - AU$0.0017 loss per share

CEO

테뉴어

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간